Iovance Biotherapeutics, Inc.
(NASDAQ : IOVA)

( )
IOVA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corp.
0.10%108.241.3%$1607.19m
AMGNAmgen, Inc.
1.02%227.821.3%$571.14m
BIIBBiogen, Inc.
1.07%288.461.4%$565.61m
GILDGilead Sciences, Inc.
1.31%65.731.0%$410.71m
ILMNIllumina, Inc.
-0.65%312.853.5%$332.16m
VRTXVertex Pharmaceuticals, Inc.
0.20%215.501.9%$314.83m
REGNRegeneron Pharmaceuticals, Inc.
1.90%350.782.6%$287.08m
EXASEXACT Sciences Corp.
-5.85%79.0224.0%$211.83m
ALXNAlexion Pharmaceuticals, Inc.
0.92%109.532.0%$182.47m
BMRNBioMarin Pharmaceutical, Inc.
-0.47%77.074.3%$133.99m
SRPTSarepta Therapeutics, Inc.
1.83%104.1714.6%$129.42m
SGENSeattle Genetics, Inc.
-0.78%119.906.1%$124.30m
AAgilent Technologies, Inc.
-0.28%78.301.6%$105.86m
BGNEBeiGene Ltd.
2.47%208.342.1%$96.02m
NBIXNeurocrine Biosciences, Inc.
0.59%113.755.0%$93.68m

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.